Assessment of Protection and Reduction of Complications caused by SARS-CoV-2 in Children Immunized with the Bacillus Calmette-Guérin Vaccine

Abstract

Introduction: The Bacillus Calmette-Guérin (BCG) vaccine, traditionally used to prevent tuberculosis, has been the subject of recent studies investigating its potential protective effect against other infections, including SARS-CoV-2. This study aims to assess whether children vaccinated with BCG have fewer complications from COVID-19 compared to unvaccinated children. Objective: The study aims to determine the effectiveness of the BCG vaccine in reducing complications associated with COVID-19 in children using a public health data analysis approach. Method: This is a cohort study that will analyze public health data from children vaccinated and not vaccinated with the vaccine in question. Data from medical records will be collected, including incidence of serious COVID-19 complications, hospitalizations, and mortality. Statistical analysis will be performed to compare the two groups, adjusting for possible confounding variables. Results and Discussion: Preliminary results indicate that children vaccinated with BCG have a lower rate of serious complications from COVID-19 compared to unvaccinated children. Statistical analysis showed a significant difference in the incidence of hospitalizations and mortality between the two groups. The findings suggest that the BCG vaccine may offer additional protection against serious complications of COVID-19 in children. The discussion will address possible biological explanations for this effect, as well as implications for public health policy and future research. Conclusion: The study concludes that BCG vaccination is associated with a significant reduction in serious complications from COVID-19 in children. These results support the need for further studies to confirm these findings and explore the mechanisms underlying this protection.